EFFECT OF DIFFERENT DOSES OF ROSUVASTATIN ON SERUM HDL SUBTYPES IN PATIENTS WITH HYPERLIPIDEMIA AND CORONARY HEART DISEASE

Qingkai Yan¹, Yan Peng ², Peng Cai², Xukai Wang^{2, #, *}, Changqing Yu^{1, #, *}

¹Department of Cardiology, The Bishan Hospital of Chongqing, Chongqing, China - ²Department of Cardiology, Daping Hospital, the Third Military Medical University, Yuzhong District, Chongqing, China

Objective: Analyze the effect of different doses of rosuvastatin on serum high-density lipoprotein cholesterol (HDL-C) subtypes in patients with hyperlipidemia and coronary heart disease. 

Methods: A sample of 300 patients with hyperlipidemia complicated with coronary heart disease in our hospital from May 2017 to April 2019 were selected as the research objects. According to their different dosages, the patients were divided into an experimental group (rosuvastatin 20 mg/d, 150 cases) and a control group (rosuvastatin 10 mg/d, 150 cases). The blood lipid levels of the two groups were compared before and after treatment. The levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), liver and kidney function (alt, AST, SCR, BUN), HDL subtypes (HDL2b, HDL3) and C-reactive protein (CRP) were measured, and the incidence of adverse reactions was recorded.

Results: After treatment, TC, LDL-C and CRP were significantly lower than those before treatment in the two groups. AST, alt, SCR and BUN, were significantly higher than those before treatment (P<0.05). LDL-C levels in the experimental group were significantly lower than those measured in the control group (P<0.05), and there was no significant difference in TC, TG, HDL-C and CRP between the two groups after treatment (P>0.05). After treatment, the levels of HDL2b and HDL3 in the two groups were significantly higher than those measured before treatment (P<0.05), but there was no significant difference in the levels of HDL2b and HDL3 between the two groups after treatment (P>0.05). The incidence of adverse reactions was 6.67% in the experimental group and 4.00% in the control group, and there was no significant difference between the two groups (P>0.05). 

Conclusion: 20 mg and 10 mg doses of rosuvastatin have effects on serum HDL subtypes in patients with hyperlipidemia and coronary heart disease, and this changes the structure and function of high-density lipoproteins. High-dose rosuvastatin can be used in clinical treatment, which can significantly and safely reduce the level of LDL-C with a significant clinical effect.